Clinical trial · Interventional
Atamparib in Patients With Advanced Solid Tumors
A Phase Ib/II Study of Atamparib in Patients With Advanced Solid Tumors
NCT07374419CI-TRIAL-00119687PARP7recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NSCLC Adenocarcinoma | — | UNRESOLVED | — |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| atamparib escalation levels | Drug | — | UNRESOLVED |
| atamparib RP2D | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- monotherapy escalation
- description
- Atamparib
- interventionNames
- Drug: atamparib escalation levels
- type
- EXPERIMENTAL
- label
- Espansion Arm a
- description
- Atamparib
- interventionNames
- Drug: atamparib RP2D
- type
- EXPERIMENTAL
- label
- Expansion Arm b
- description
- Atamparib
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Subject must be ≥18 years of age. 2. Histologically confirmed diagnosis of unresectable advanced or metastatic NSCLC adenocarcinoma. 3. Documented KRAS mutation status at study entry. 4. Have received at least one line of standard therapy and experienced radiographic tumor progression to the last administered treatment and have failed institutional standards of care. 5. Have measurable tumor lesions 6. ECOG 0-1 7. Adequate organ functions Exclusion criteria: 1. Non-adenocarcinoma histology of NSCLC. Patients whose tumors have a mixed histology are ineligible. 2. Wtih oncogenic driver mutation other than KRAS for which an approved therapy is available but not adequately treated. 3. Known active GI disease that would impact the absorption 4. Clinically significant cardiac disease 5. Requiring the administration of strong inhibitors or inducers of CYP3A4, P-gp or BCRP. 6. Symptomatic, or untreated CNS lesions.
References
Publications (0)
Data not yet available
No reference posted for this study.